

January 4, 2022



Poxel Announces Financial Calendar for 2022

LYON, France--(BUSINESS WIRE)-- [POXEL SA](#) (Euronext – POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced its calendar for the publication of financial information for 2022.

Event	Date*
2021 Fourth Quarter Financial Update	February 16, 2022
2021 Annual Results	March 23, 2022
2022 First Quarter Financial Update	May 17, 2022
2022 Second Quarter Financial Update	August 30, 2022
2022 First Half Results	September 21, 2022
2022 Third Quarter Financial Update	November 8, 2022
2022 Fourth Quarter Financial Update	February 15, 2023

* Subject to modification.

All corporate information on Poxel, including financial statements, press releases and corporate presentations, is available on the [Investors](#) page of the Company's website.

About Poxel SA

Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. Poxel has clinical and earlier-stage programs from its adenosine monophosphate-activated protein kinase (AMPK) activator and deuterated TZD platforms targeting chronic and rare metabolic diseases. For the treatment of NASH, PXL065 (deuterium-stabilized *R*-pioglitazone) is in a streamlined Phase 2 trial (DESTINY-1). PXL770, a first-in-class direct AMPK activator, has successfully completed a Phase 2a proof-of-concept trial for the treatment of NASH, which met its objectives. For the rare inherited metabolic disorder, adrenoleukodystrophy (ALD), the company intends to initiate Phase 2a proof of concept studies with PXL065 and PXL770 in patients with adrenomyeloneuropathy (AMN). TWYMEEG® (Imeglimin), Poxel's first-in-class lead product that targets mitochondrial dysfunction, has been approved and launched for the treatment of

type 2 diabetes in Japan. Poxel expects to receive sales-based payments and royalties from Sumitomo Dainippon Pharma. Poxel has a strategic partnership with Sumitomo Dainippon Pharma for Imeglimin in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

For more information, please visit: www.poxelpharma.com

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20220104005717/en/>

Poxel SA

Aurélie Bozza

Investor Relations & Communication Senior Director

aurelie.bozza@poxelpharma.com

+33 6 99 81 08 36

Elizabeth Woo

Senior Vice President, Investor Relations & Communication

elizabeth.woo@poxelpharma.com

Investor relations / Media

NewCap

Emmanuel Huynh or Arthur Rouillé

poxel@newcap.eu

+33 1 44 71 94 94

Source: POXEL SA